Not all cementless femoral stems are created equal but the results may be comparable
| Autor: | S. W. Carlson, Steve S. Liu, John J. Callaghan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male Reoperation musculoskeletal diseases medicine.medical_specialty Surface Properties Arthroplasty Replacement Hip Radiography Kaplan-Meier Estimate Prosthesis Design Cohort Studies Young Adult 03 medical and health sciences 0302 clinical medicine Survivorship curve Humans Medicine Prosthesis design Orthopedics and Sports Medicine Prospective Studies 030212 general & internal medicine Cementation Aged Aged 80 and over 030222 orthopedics business.industry Bone Cements Middle Aged equipment and supplies Prosthesis Failure Surgery Treatment Outcome Female Hip Prosthesis business Porosity Follow-Up Studies |
| Zdroj: | The Bone & Joint Journal. :14-17 |
| ISSN: | 2049-4408 2049-4394 |
| DOI: | 10.1302/0301-620x.99b1.bjj-2016-0269.r1 |
| Popis: | Aims The aim of this study was to compare the survivorship and radiographic outcomes at ten-year follow-up of three prospective consecutive series of patients each of which received a different design of cementless femoral components for total hip arthroplasty (THA). Patients and Methods In Cohort 1, 91 consecutive patients (100 hips) underwent THA with a cementless porous-coated anatomic femoral stem (PCA) between October 1983 and January 1986. In Cohort 2, 86 consecutive patients (100 hips) underwent THA with an extensively porous-coated cementless femoral stem (Prodigy) between June 1994 and October 1997. In Cohort 3, 88 consecutive patients (100 hips) underwent THA with a proximally porous-coated triple-tapered cementless stem (Summit) between April 2002 and October 2003. All three groups underwent prospective clinical and radiographic evaluation. Results Kaplan-Meier survivorship analysis of Cohort 1 was 91% (95% confidence interval (CI) 88 to 94) with an endpoint of revision for any reason and 97% (95% CI 95 to 99) with aseptic loosening as the endpoint. Survivorship of Cohort 2 was 88% (95% CI 79 to 97) for revision for any reason and 100% for aseptic loosening. Survivorship of Cohort 3 was 95% (95% CI 91 to 99) for revision for any reason and 100% with aseptic loosening as the endpoint. Conclusion With revision for aseptic loosening of the femoral component as the endpoint, the three femoral components with different design philosophies demonstrated excellent survivorship, ranging from 97% to 100% at ten years. Cite this article: Bone Joint J 2017;99-B(1 Supple A):14–17. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|